A study by researchers from Oregon State University and the Linus Pauling Institute showed CBDA and CBGA block cellular entry of SARS-CoV-2 and the emerging variants from entering human cells. Links to study and summary story are below. This research was published in scientific journal Journal of Natural Products (American Chemical Society) on January 10, 2022.
Tay’s Hemp tinctures & gummies are approximately 60-70% CBDA, 15-20% CBGA cannabinoids.
“These compounds (CBDA and CBGA) can be taken orally and have a long history of safe use in humans. They have the potential to prevent as well as treat infection by SARS-CoV-2. One of the primary concerns in the pandemic is the spread of variants, of which there are many, and B.1.1.7 and B.1.351 are among the most widespread and concerning. These variants are well known for evading antibodies against early lineage SARS-CoV-2, which is obviously concerning given that current vaccination strategies rely on the early lineage spike protein as an antigen. Our data show CBDA and CBGA are effective against the two variants we looked at, and we hope that trend will extend to other existing and future variants.” – Richard van Breemen, Ph.D. study lead researcher with Oregon State’s Global Hemp Innovation Center – College of Pharmacy and Linus Pauling Institute, from KVAL-13 News website story 1/11/22
FULL STUDY – Journal of Natural Products (American Chemical Society):
ABSTRACT – National Library of Medicine (National Institute of Health):
KVAL-13 News. OSU Study: Compounds in hemp block Covid-19 from entering human cells.
1/11/22 News staff